Fiber intake and plasminogenactivatorinhibitor-1 in type 2 diabetes: Look AHEAD (Action for Health in Diabetes) trial findings at baseline and year 1.
Plasminogen activator inhibitor 1 (PAI-1) is increased in obese patients with type 2 diabetes and can contribute, independently of traditional factors, with an increased risk of cardiovascular disease. fiber intake can reduce levels of PAI-1. We examined the association of dietary fiber intake and changes with PAI-1 prior to and during the intensive intervention lifestyle (ILI) to lose weight in 1701 FRONT View (Health Action in Diabetes) participants with diet, fitness, and PAI-1 data at baseline and 1 year.
Look AHEAD is a randomized trial of cardiovascular disease in 5145 overweight / obese patients with type 2 diabetes, comparing ILI (≥7% weight reduction goals baseline) with a control group of diabetes support and education. ILI participants are encouraged to consume vegetables, fruits, and whole grain products are low in sugar and fat. At baseline, the average fiber intake is 17.9 g / day. Each 8.3 g / day higher fiber intake was associated with a 9.2% lowering PAI-1 levels (P = 0.008); This association persisted after adjustment weight and fitness (P = 0.03). The higher initial intake of fruit (P = 0.019) and high-fiber wheat and cereals (P = 0.029) associated with lower levels of PAI-1.
Although it managed to increase the weight and physical fitness at 1 year, the ILI in Look AHEAD resulted in a small increase in the intake of fiber (4.1 g / day, compared with -2.35 g / day with a diabetes support and education) were not associated with PAI- 1 changes (P = 0.34). Only 31.3% of ILI participants (39.8% female, 19.1% male) meet daily fiber intake recommendations. Increasing fiber intake in overweight / obese individuals with diabetes are interested in weight loss challenge. future studies evaluate changes in fiber intake during weight loss interventions is guaranteed.
Fiber intake and plasminogenactivatorinhibitor-1 in type 2 diabetes: Look AHEAD (Action for Health in Diabetes) trial findings at baseline and year 1.
The interaction of cell adhesion molecules CHL1 with vitronectin, integrins, and plasminogen driving inhibitors – two promote the development induced CHL1- neurite and neuronal migration.
The cell adhesion molecule close homolog of L1 (CHL1) plays an important functional role in the developing and adult nervous system. In looking for a partner binding that mediates the function of diverse and sometimes opposite of CHL1, extracellular matrix-associated protein vitronectin and plasminogen activator inhibitor-2 (PAI-2) was identified as a partner interaction CHL1 novel and tested for involvement in CHL1-dependent functions during mouse development cerebellum.
CHL1-induced cerebellar neurite and cell migration results in postnatal days 6-8 were inhibited by a peptide derived CHL1 consisting of integrin binding RGD motif, and with antibodies against vitronectin or some integrins, showed integrin-mediated pathway-dependent vitronectin. A PAI-2 derived peptide, or antibody against PAI-2, urokinase type of plasminogen activator (uPA), uPA receptor, and some of the integrin reduces cell migration.
CHL1 colocalized with vitronectin, PAI-2, and some of the integrin in cerebellar granule cells, show an association between these proteins. Interestingly, on a slightly earlier age 4-5 d, cerebellar neurons do not depend on CHL1 to neuritogenesis and cell migration. However, the differentiation of progenitor cells into neurons at this stage depends on CHL1-CHL1 homophilic interaction.
Description: A competitive ELISA for quantitative measurement of Canine Plasminogen Activator Inhibitor 2 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Canine Plasminogen Activator Inhibitor 2 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Canine Plasminogen Activator Inhibitor 2 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Rat Plasminogen Activator Inhibitor 2 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Rat Plasminogen Activator Inhibitor 2 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Rat Plasminogen Activator Inhibitor 2 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Porcine Plasminogen Activator Inhibitor 2 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Porcine Plasminogen Activator Inhibitor 2 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Porcine Plasminogen Activator Inhibitor 2 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Goat Plasminogen Activator Inhibitor 2 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Goat Plasminogen Activator Inhibitor 2 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Goat Plasminogen Activator Inhibitor 2 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Mouse Plasminogen Activator Inhibitor 2 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Mouse Plasminogen Activator Inhibitor 2 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Mouse Plasminogen Activator Inhibitor 2 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
These observations suggest that homophilic CHL1 trans-interactions regulate the differentiation of progenitor cells nerve at the stage of early postnatal, while heterophilic trans-interaction CHL1 with vitronectin, integrins, and the system is plasminogen activator set neuritogenesis and migration of nerve cells at a later stage after the birth of cerebellar morphogenesis , Thus, in a very narrow time window in postnatal cerebellar development, the different types of molecular interactions mediated by CHL1 underlying the diverse functions of these proteins.
